Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Dominique Surleraux | M | - |
BCI Pharma SAS
 BCI Pharma SAS BiotechnologyHealth Technology BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France. | 11 anni |
| Elisabeth Picou | M | - |
BCI Pharma SAS
BCI Pharma SAS BiotechnologyHealth Technology BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France. | 11 anni |
| Didier Malherbe | M | - |
BCI Pharma SAS
BCI Pharma SAS BiotechnologyHealth Technology BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France. | 4 anni |
| Jean-Marc Legrand | M | - |
BCI Pharma SAS
BCI Pharma SAS BiotechnologyHealth Technology BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France. | 7 anni |
| Frederic Schynts | M | - |
BCI Pharma SAS
BCI Pharma SAS BiotechnologyHealth Technology BCI Pharma SAS engages in research and development in biotechnology. Its kinase platform is based on a new chemotype with phys-chem properties, able to explore a new chemical space for treating CNS, inflammation, cancer and metabolic diseases. The firm also offers medicinal chemistry, HTS platform and consultancy services. The company was founded by Elisabeth Picou and Dominique Surleraux in March 2013 and is headquartered in Grabels, France. | 5 anni |
Grafico relazionale
Relazione in diverse aziende
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Francia | 5 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Cyril Dousson
- Contatti personali
